Polfa Warszawa S.A. is one of the largest Polish pharmaceutical companies. It has been delivering top quality products for over 190 years.
In 2003, the company was transformed into a sole-shareholder company of the State Treasury, and between 2004 and 2012 it was part of the Polski Holding Farmaceutyczny S.A. On 19 April 2012, as a result of privatization, Polfa Warszawa joined the Polpharma Group.
Polfa Warszawa's portfolio includes over 140 different medicines which are distributed on the domestic market, but also exported to several dozen countries across the globe. Its most popular product is ACARD.
The company has a special place within the Polpharma Group and is the center of excellence for the production of sterile and ophthalmic medicines. The company's products include injection medicines, nasal drops and eye drops. Production conditions at Polfa Warszawa meet the highest standards of purity applicable to sterile production. The company develops, for example, preservative-free eye drops, which are a unique product of this kind on the market.
Polfa places special emphasis on using state-of-the-art production technology which guarantees high quality and safety of the medicines manufactured as well as compliance with all applicable standards regarding the environment.
The unchanging mission of Polfa Warszawa is to manufacture top quality medicines which are accessible to anyone. The company continues to pursue its goal, providing efficient health care to new generations of Poles. Polfa's primary manufacturing plant is located at the Karolkowa street in Warsaw.
Since 2015, Polfa Warszawa S.A. has been working on a key investment for Polpharma Group. In Duchnice near Warsaw, a new plant is being built. When completed, it will be one of the most modern pharmaceutical works in Europe.